Tocqueville Asset Management’s Cognition Therapeutics CGTX Stock Holding History

Tocqueville Asset Management’s Portfolio CGTX Stock Details CGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$148K	Buy	195,000 +2,500	+1%	+$2.91K	﹤0.01%	535
2025 Q4	$260K	Buy	192,500 +30,000	+18%	+$48.7K	﹤0.01%	530
2025 Q3	$219K	Buy	162,500 +134,000	+470%	+$183K	﹤0.01%	530
2025 Q2	$8.83K	Hold	28,500	–	–	﹤0.01%	535
2025 Q1	$12K	Hold	28,500	–	–	﹤0.01%	513
2024 Q4	$20K	Buy	28,500 +5,000	+21%	+$2.47K	﹤0.01%	536
2024 Q3	$11K	Sell	23,500 -16,500	-41%	-$17K	﹤0.01%	527
2024 Q2	$66.4K	Buy	40,000 +14,000	+54%	+$27.9K	﹤0.01%	519
2024 Q1	$47.3K	Buy	+26,000	New	+$53.7K	﹤0.01%	531

Other funds holding CGTX

BCM

BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HCM

Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

DIG

Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Tocqueville Asset Management's CGTX Position: Q1 2026 in Review

Tocqueville Asset Management increased its Cognition Therapeutics (CGTX) stake by 1.3% in Q1 2026, buying an estimated $2.91K and bringing the position to 195,000 shares worth $148K. The position accounts for ﹤0.01% of the portfolio, ranked #535.

Tocqueville Asset Management first reported a position in CGTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $260K in Q4 2025. 75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

Tocqueville Asset Management held 195,000 shares of Cognition Therapeutics worth $148K as of Q1 2026.
Tocqueville Asset Management bought 2,500 Cognition Therapeutics shares in Q1 2026, an estimated $2.91K.
Cognition Therapeutics made up ﹤0.01% of Tocqueville Asset Management's portfolio in Q1 2026, its #535 holding.
Tocqueville Asset Management first reported a position in Cognition Therapeutics in Q1 2024 and has held it in 9 quarters since.
Tocqueville Asset Management's Cognition Therapeutics position peaked at $260K in Q4 2025.
75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on Tocqueville Asset Management's 13F filing for Q1 2026, filed 12 May 2026.